Short-term Prostate-specific Antigen Pseudoregression Following [ 177 Lu]-Prostate-specific Membrane Antigen Therapy : Tackling Prostate-specific Antigen Decline Limitations in Patient With Metastatic Castration-resistant Prostate Cancer.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40524356.
- Also identified by DOI 10.1097/RLU.0000000000005792.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 74-year-old man with metastatic castration-resistant prostate cancer underwent 2 cycles of [ 177 Lu]Lu-prostate-specific membrane antigen (PSMA) therapy. Despite declining prostate-specific antigen (PSA) levels and pain relief throughout the first 4 months of [ 177 Lu]Lu-PSMA therapy, follow-up [ 68 Ga]Ga-PSMA PET/CT revealed progressive skeletal involvement. A bone marrow biopsy confirmed fulminant metastatic castration-resistant prostate cancer infiltration. This case exemplifies PSA pseudoregression, where PSA suggests disease control while imaging shows progression. The patient's condition deteriorated, leading to intensive care admission and death.
Medical subject headings
- Prostatic Neoplasms, Castration-Resistant
- Prostate-Specific Antigen
- Lutetium
- Antigens, Surface
- Glutamate Carboxypeptidase II